Trillium Ag Overview
Trillium Ag is a Washington State agricultural biotechnology platform company founded in 2016. It is trying to solve the problem that has kept RNA interference from becoming a mainstream crop-protection category: naked double-stranded RNA breaks down quickly, crosses membranes poorly, and most economically important insect pests do not respond to it when they ingest it.
The company's Agrisome platform takes a different approach to each of these problems. It uses a single-stranded, structurally engineered RNAi trigger. It packages that trigger in programmable protein nanoparticles, which can also be loaded into engineered exosomes and stabilised in natural crystals for field use. AI-assisted sequence and particle design tools sit on top.
Trillium does not intend to become a vertically integrated pesticide maker. Its plan is to be an enabling-technology licensor and co-development partner to established crop-protection companies. A second business, the nPlanta plant-based cell-free protein expression kit, gives it an early source of product revenue and a research tool that also has customers in pharma and biotech.
What the company does
Trillium Ag develops biological crop-protection technology based on RNA interference. RNAi is a natural cellular process in which a short RNA sequence matching a target gene leads to that gene's messenger RNA being destroyed, which silences the gene. Silencing a gene essential to a pest's survival can kill the pest, or stop it feeding or reproducing. Because the sequence can match genes found only in the target species, the method is potentially far more selective than broad-spectrum synthetic chemistry.
The company's website states its long-term ambition plainly: crop protection that defends yields without damaging the surrounding ecosystem. It says Agrisome addresses insects, weeds, fungi and other pests. The only disclosed proof-of-concept (POC) data, however, cover three insect orders: Lepidoptera (moths and caterpillars), Coleoptera (beetles) and Hemiptera (true bugs such as aphids and stink bugs).
Company's own description (paraphrased; no annual report exists)
Trillium Ag has no annual report. Its self-description on trillium.ag, accessed October 2026, is the closest substitute. In paraphrase, the company says it develops new biological platforms for more precise and sustainable crop protection, and that its nature-inspired, AI-designed Agrisome platform has finally delivered on RNAi's potential against insects, weeds, fungi and other pests. It says it is currently helping partner companies build a new class of field-ready biological protectants.
An older directory description, carried over from the company's earlier materials, describes a portfolio of RNAi-based biologicals for crop protection, plant health and yield. That portfolio rested on a patented RNAi trigger called MV-RNA (cited as US Patent 9,200,276) and on nanoparticles for transient or stable trait activation (VisualVisitor profile).
Independent characterisation
Trillium Ag is a pre-commercial, IP-led platform biotech. Its economics depend on licensing and partnering, much like a pharma drug-discovery platform. Its development path is long, regulated and capital-hungry: discovery, then greenhouse trials, then field trials, then regulatory registration (EPA under FIFRA in the US, with equivalent agencies elsewhere), then commercial launch. Each stage can take years.
The company's public positioning moved over 2023–2026:
2023: "Agrisome" was described as a protein-coated RNA biological that Trillium intended to take from R&D to broad-acre use.
2026: Trillium describes itself as a partner-enablement platform. It offers platform licences, co-development programmes, and licence-ready compositions, and it has added AI design tools and a proprietary bioproduction system (nPlanta).
The direction of travel is from "we will make products" towards "we make the toolkit and the IP that major crop-protection companies will license." This is a capital-light strategy that suits a very small team.
Business and revenue model
| Revenue model element | Description | Status |
|---|---|---|
| Platform licensing | A partner receives broad access to the Agrisome platform across products and categories | Offered (website); no disclosed signed licences |
| Co-development | Trillium runs specific programmes with a partner to feed the partner's development pipeline; typically funded R&D plus milestones and royalties (industry norm; Trillium's terms n/d) | Offered; trade press (2023) cites "several ongoing collaborations" with unnamed commercial and academic partners |
| Composition licensing | Licence-ready proof-of-concept compositions against Lepidoptera, Coleoptera and Hemiptera targets | Offered |
| Product sales – nPlanta | Cell-free protein expression lysate, reaction buffers, vectors and scalable formats, sold through an e-commerce storefront (shopping cart and account login on nplanta.com) | Commercial; revenue n/d |
| Mix (product / service / licensing) | — | — |
Value-chain position
Trillium sits at the very start of the crop-protection value chain, in upstream discovery and enabling technology. Downstream are:
-
Agrochemical and biologicals majors (Bayer, Syngenta, Corteva, BASF, FMC, UPL and others), which handle development, registration, manufacturing and distribution.
-
Ag retailers and distributors.
-
Growers.
nPlanta places Trillium in a second value chain as well: life-science research tools, where it sells to R&D labs in medicine, agriculture and biotechnology.
Customer types and end-markets
| Customer type | Offering | End-market |
|---|---|---|
| Global crop-protection companies | Platform / co-development / composition licences | Insecticides and biopesticides; potentially fungicides and herbicides |
| Seed and trait companies | Crystal formats described as compatible with seed traits | Seed treatments and traits |
| Academic research partners | Collaborations (unnamed) | Research |
| Pharma, biotech and ag R&D labs | nPlanta cell-free expression kits | Protein expression and research reagents |
Strategy
Stated strategic themes (paraphrased from trillium.ag, 2026 and 2023 press releases)
-
Ending the trade-off between yield and biodiversity. The company's stated vision is that crop protection should eventually defend crops without harming nature.
-
Realising RNAi in agriculture. Its stated view is that earlier dsRNA approaches failed on stability, specificity and membrane crossing, and that Agrisome's redesigned trigger and delivery system solve those problems.
-
Partner enablement over vertical integration. Trillium positions itself as a collaborator to global crop-protection companies through three models: platform licensing, co-development and composition licensing.
-
AI-accelerated design. The 2026 messaging adds "designed with AI" and a proprietary AI toolstack for sequence and particle design.
-
Scalable bioproduction. nPlanta is presented as the bridge from R&D supply to greenhouse trials, which reduces scale-up friction for partners.
-
Multi-modal resistance management. Combining RNAi with modes of action from the protein shell is pitched as a way to delay pest resistance.
Strategic initiatives (last 24 months, Oct 2024–Oct 2026)
| Initiative | Timing | Description | Source |
|---|---|---|---|
| nPlanta commercialisation | 2024–2025 | Brand set up c. mid-2024; product site and e-commerce refreshed June 2025 | nplanta.com |
| Platform expansion: engineered exosomes | By Jan 2026 | Second delivery layer added for tissue and species specificity | trillium.ag |
| Platform expansion: field-ready crystals | By Jan 2026 | Stabilisation format compatible with seed traits | trillium.ag |
| AI toolstack | By Jan 2026 | Proprietary design and optimisation software | trillium.ag |
| Formal partnering menu | By Jan 2026 | Three-tier licensing and co-development offer | trillium.ag |
| Pest coverage claim widened | By Jan 2026 | Messaging extended from insects to weeds, fungi and other pests | trillium.ag |
Medium-term targets and guidance
None disclosed. No financial targets, cost programmes or ESG commitments with quantified goals have been published.
Products & Services
Agrisome Platform (crop protection)
| # | Component | Description and capabilities | Target customer | Launch / version | Pricing |
|---|---|---|---|---|---|
| 1 | Novel RNAi Trigger (single-stranded; historically branded MV-RNA, "multivalent RNA") | A single-stranded, structurally designed RNAi trigger. The company contrasts it with traditional dsRNA, which it says has been problematic in agriculture, and claims higher crop-protection efficacy. Hauser has said the redesigned trigger activates RNAi as strongly as the Nobel-winning dsRNA (AgTech News Substack). The "multivalent" name implies one molecule can target several sequences at once, which matters for resistance management | Crop-protection licensees | Core IP from the 2010s (US 9,200,276 cited) | — |
| 2 | Programmable Nanoparticle (protein shell) | Several triggers are assembled into a nanostructure that can be "programmed" to bind a specific set of proteins for each target species or class. The protein shell is said to improve stability, targeting, delivery, uptake and potency, and to add modes of action beyond RNAi. In 2023 trade press this was described as naturally derived, protein-coated RNA | Same | Described publicly since 2023 | — |
| 3 | Engineered Exosomes | The nanoparticles can be packaged inside exosomes, natural extracellular vesicles that act as a second, biologically native targeting layer. Claimed benefits: tunable tissue and species specificity, protection in harsh environments such as the insect gut, and a modular route to higher potency and more consistent field performance | Same | First disclosed in the Jan 2026 site update | — |
| 4 | Field-Ready Crystals | Nanoparticles, including those inside exosomes, can be locked into natural crystals for long shelf life ("barn-safe" stability). The crystals are described as compatible with seed traits and programmable for just-in-time release of the cargo, and as simplifying production and application. (Analyst note: this resembles how Bt Cry proteins naturally form crystals, a format Fischhoff's Monsanto career was closely tied to.) | Same; seed/trait companies | First disclosed 2026 | — |
| 5 | AI-Driven Toolstack | Proprietary software that speeds up sequence design and particle composition for each pest and use case, plus tools for bioproduction, formulation and screening | Partners (bundled with licences) | First disclosed 2026 | — |
| 6 | Composition library (POCs) | Licence-ready proof-of-concept compositions against Lepidoptera, Coleoptera and Hemiptera targets | Composition licensees | Current | — |
| 7 | "Bio-agricultural pipeline" (unspecified) | Further sustainable bio-ag products in R&D, referred to in 2023 press releases | — | — | — |
| 8 | Trait-activation nanoparticles (legacy description) | Nanoparticles for transient or stable trait activation in plants, aimed at plant health and yield, not only pest control | Seed/trait companies | Legacy description; current status n/d | — |
Claimed platform attributes (trillium.ag, 2026): more effective; greater specificity with less harm to beneficial organisms; farm-ready stability; a multi-mode advantage for resistance management; adaptive and programmable design that is not rebuilt for each new pest; broad, durable IP protection; and ease of scaling for partners.
nPlanta Cell-Free Protein Expression System
| # | Product | Description and specifications | Target customer | Launch | Pricing |
|---|---|---|---|---|---|
| 1 | nPlanta base lysate | Plant-based cell-free lysate for protein expression. Claims eukaryotic-quality folding, disulfide bonds and post-translational modifications (phosphorylation, glycosylation) | Pharma, biotech and ag R&D labs | Brand set up c. mid-2024; marketed 2025 | Listed via e-commerce; prices n/d in sources reviewed |
| 2 | Specialised reaction buffers | A library of buffers, each optimised for a particular expression need; used with the lysate plus DNA | Same | 2,025 | — |
| 3 | Optimised vectors (plasmids) | Vectors tuned for faster reactions, complex eukaryotic proteins and post-translational modifications | Same | 2,025 | — |
| 4 | Scalable formats | Reaction volumes from 10 µL up to litres, covering prototyping, screening and bioassay validation ahead of industrial biomanufacturing | Same | 2,025 | — |
| 5 | Workflow | Two-part system: combine lysate and buffer, add the vector carrying the gene, incubate 24–48 hours, collect protein | Same | 2,025 | — |
| 6 | Target protein classes | GPCRs, cytokines, membrane-bound proteins, glycoproteins, exosomes, virus-like particles (VLPs), enzymes, and multimeric or toxic proteins | Same | — | — |
| 7 | Custom project support | Consultation for difficult targets through a contact form | Same | — | — |
nPlanta's stated advantages: protein expression in 24–48 hours (versus weeks in cell culture); no cell culture or sterile facility needed; rapid onboarding; and use alongside existing expression systems.
Financial Narrative
Trillium Agriculture, Inc. is private and has published no financial statements. All values below are not publicly disclosed. The table structure is kept as required, with blank year cells. It should be treated as unreliable.
Income statement
Revenue CAGR FY2021–FY2025: not publicly disclosed.
Commentary
No reported numbers exist, so the analysis below is structural: it describes the likely financial profile implied by the business model, not measured results.
-
Revenue composition. Revenue most likely comes from three sources: (a) nPlanta reagent sales, probably small and early-stage; (b) sponsored-research or evaluation fees from undisclosed crop-protection collaborators; and (c) possibly government grants. Milestone or royalty income from Agrisome is unlikely before a partner product is registered.
-
Profitability. Companies at this stage are normally loss-making and funded by equity. Gross margin on reagents can be high, but the scale is too small to cover R&D.
-
Balance sheet. The company's main asset is its intellectual property, which is unlikely to be capitalised on the balance sheet, and its cash runway. No disclosed debt.
-
Cash flow. Operating cash burn is driven by R&D salaries, lab costs and patent prosecution. Capex should be modest because the company runs a small lab and outsources field work.
-
Key financial monitorable. The size and terms of any first platform or composition licence. That deal would be the first external validation of the IP's value.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Lines
| Business line (analyst-defined) | Contents | Products / services | Commercial stage |
|---|---|---|---|
A. Agrisome Crop-Protection Platform | RNAi trigger IP, programmable nanoparticles, engineered exosomes, field-ready crystals, AI toolstack, composition library | Platform licences, co-development, composition licences | Pre-commercial / partnering |
B. nPlanta Bioproduction | Plant-based cell-free transcription/translation (TX/TL) system | Lysate, reaction buffers, optimised vectors, scalable reaction formats | Commercial (e-commerce) |
Capital Markets
| Item | Status |
|---|---|
Share price performance (1 / 3 / 5-year) | Not applicable (private) |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Analyst Conclusions
Management guidance
None published. The company's stated near-term focus is moving Agrisome from R&D to broad-scale use through partners (2023 press releases), and scaling partner adoption through nPlanta and its AI tools (trillium.ag, 2026).
Consensus expectations
None (no analyst coverage).
Bull case
-
Technical differentiation in the category's hardest problem. If the protein-shell, exosome and crystal stack really does work against insect orders that resist orally ingested dsRNA (about 85% of pests, by Hauser's figure), Trillium holds a key that dsRNA producers lack.
-
Network-driven route to licensing. With Gutterson (former Corteva CTO) on the board and Fischhoff (Monsanto's Bt pioneer) chairing the SAB, Trillium has direct access to the decision-makers who sign platform deals.
-
Capital-light optionality. Three licensing models, POCs in three insect orders, and a reagent business generating cash give multiple ways to win without building a sales force.
Bear case
-
Ten years without a named partner. The company was founded in 2016 and still discloses no named licensee, field data or regulatory filing. That points to slow validation.
-
A competitor has already set the benchmark. GreenLight's registered dsRNA product and its large-scale production weaken Trillium's argument that dsRNA cannot work, at least for beetles.
-
Execution and financing fragility. A team possibly as small as 3, undisclosed finances, and complex multi-layer constructs create risk on runway, cost of goods and regulatory approval.
Key catalysts and monitorables (next 12 months)
| Catalyst / Monitorable | Why it matters |
|---|---|
| Announcement of a named platform or composition licence | First external validation of the value of the IP |
| Disclosure of greenhouse or field-trial data | Evidence that the technology works under real conditions |
| Any EPA Experimental Use Permit or registration filing | Start of the regulatory path |
| Funding round disclosure (or SEC Form D) | Runway and investor validation |
| nPlanta customer wins or distribution partnerships | Strength of the non-dilutive revenue line |
| Leadership hires (CBO, CSO, regulatory head) | Signal of a move to commercial scale |
| Competitor moves (GreenLight expansion, majors' internal RNAi) | Pressure on the competitive window |
| New patent grants (exosome, crystal formats) | Durability of the IP |
Analyst verdict
Trillium Agriculture, Inc. is not the listed company the input record assumed. It is a small, private, IP-intensive ag-biotech platform with an ambitious scientific thesis and an elite advisory bench, but very little public evidence of commercial traction. Any institutional reader should start from that fact. No financial statements, valuation or ownership data exist in the public domain, and none have been estimated here.
The scientific logic is coherent and well targeted. Agricultural RNAi has historically been held back by three things: dsRNA instability, poor uptake in most insect orders, and challenges with field persistence. Trillium has built a modular answer to each. Its single-stranded trigger addresses potency and specificity. The protein-shell nanoparticles and engineered exosomes address delivery and gut survival. The natural crystals address storage and controlled release. An AI design layer and the nPlanta bioproduction system speed up iteration and scale-up for partners. In 2026 the company recast itself as a licensor and co-developer rather than a product company, which is the right strategic choice for an organisation of its apparent size.
What is missing is proof outside the lab. About ten years after its founding, Trillium has named no licensee, published no field data and disclosed no regulatory filing. Meanwhile, at least one competitor has registered a sprayable RNA product in the US, which has moved the category from theory to reality. Trillium's opportunity window is real but finite. Its differentiation matters most for the insect orders and pest classes where dsRNA does not work.
Verdict: High-risk, high-optionality early-stage platform. Monitor rather than engage at scale. The decisive near-term signal is a named partnership with a global crop-protection company backed by greenhouse or field data. Until that happens, Trillium Ag should be treated as a credible but unproven technology option, and its strongest verifiable assets are its patent claims and the calibre of its board and scientific advisors.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Compensation |
|---|---|---|---|---|
Todd Hauser | Co-Founder & Chief Executive Officer | 2016–present | Described as a seasoned biotech and gene-silencing entrepreneur (AgTech News Substack); prior company affiliations not detailed in sources reviewed | n/d (private) |
Paul Olivier | Co-Founder (current title n/d; likely scientific lead) | 2016–present | Seattle-area scientist; a Seattle-area inventor (Jean) Paul Olivier holds multiple plant-biotech patents, several assigned to Targeted Growth, Inc.; link to the co-founder is plausible but unconfirmed | — |
David Hensel | Listed as "founder" by MarketScreener | — | Former Head of Media Relations and Director of Brand & Marketing at Grand Banks Yachts Ltd. | — |
Board of Directors
| Name | Role | Joined | Background | Education | Independence |
|---|---|---|---|---|---|
Todd Hauser | Director (presumed, as CEO and co-founder) | 2016 | See above | — | Non-independent (executive) |
Neal Gutterson, PhD | Director | 2023 | Partner & CTO, Radicle Growth (early-stage food and ag tech fund). Retired as CTO of Corteva Agriscience in 2020. Joined DuPont (later Corteva) in 2014. Earlier, President & CEO of Mendel Biotechnology. Board seats at CGIAR System Board (from autumn 2020), CIMMYT and the Biotechnology Innovation Organization. Chairman at Boost Biomes. Former board member at GrassRoots Biotechnology and DNA Plant Technology | BA, Yale University; PhD, UC Berkeley | Likely independent. Radicle Growth affiliation could indicate investor representation; unconfirmed |
Board of Directors — David Fischhoff, PhD
| Name | Role | Appointed | Background |
|---|---|---|---|
David Fischhoff, PhD | Chair, Scientific Advisory Board | 14 June 2023 | 33 years at Monsanto. Roles included Chief Scientist of The Climate Corporation and Co-President of Cereon Genomics (a Monsanto–Millennium Pharmaceuticals research venture). Widely credited with leading the discovery and development of insect-resistant (Bt) crops. Nearly four decades in ag R&D (iGrow News) |
Directors' Remuneration
| Item | Status |
|---|---|
Board size | n/d (at least 2 inferred) |
Committees (audit, compensation, nominating) | n/d. Unlikely to be formal at this stage |
Recent executive changes | None reported apart from the board and SAB additions in 2023 |
Institutional ownership (top 10) | Not applicable (private). Investors not publicly disclosed |
Insider ownership | n/d. Founders presumed to be significant holders |
Competitive Landscape
Key Competitors
| # | Competitor | Ownership | Relevance | Positioning vs. Trillium |
|---|---|---|---|---|
| 1 | GreenLight Biosciences | Private (taken private 2023) | Cell-free dsRNA production; ledprona (Calantha) EPA-registered Dec 2023 for Colorado potato beetle (analyst recall) | Ahead commercially with a registered product. Uses dsRNA, the approach Trillium argues against. Large-scale production cost advantage |
| 2 | Bayer Crop Science | Listed (Bayer AG) | RNAi traits (e.g., corn rootworm RNAi in SmartStax PRO); biologicals | Incumbent with trait-based RNAi; potential licensee and competitor |
| 3 | Syngenta Group (Biologicals) | Chinese state-owned (ChemChina/Sinochem) | Large biologicals portfolio; RNAi research | Potential licensee and competitor |
| 4 | Corteva Agriscience | Listed (NYSE: CTVA) | Biologicals (via Stoller and Symborg acquisitions); RNAi research history | Gutterson link; potential licensee |
| 5 | BASF Agricultural Solutions | Listed (BASF SE) | Biologicals and traits | Potential licensee |
| 6 | FMC Corporation | Listed (NYSE: FMC) | Biologicals; pheromones | Potential licensee |
| 7 | RNAissance Ag | Private | RNAi biopesticides | Direct peer (start-up) |
| 8 | AgroSpheres | Private | Bioparticle encapsulation and delivery of actives, including RNA | Direct peer on delivery |
| 9 | Pebble Labs | Private | Microbe-delivered RNA for crop and animal health | Direct peer |
| 10 | Vestaron | Private | Peptide-based bioinsecticides | Adjacent: precision biologicals for insects |
| 11 | Provivi | Private | Pheromone-based pest control | Adjacent |
| 12 | Micropep Technologies | Private | Micropeptide crop protection | Adjacent |
Peer Comparison FY2024
| Metric | Trillium Ag | Corteva (total) | Bayer Crop Science | FMC |
|---|---|---|---|---|
Revenue FY2024 | — | ≈ USD 16.9 B | ≈ EUR 22.3 B | ≈ USD 4.25 B |
Revenue growth FY2024 | — | ≈ -3% to -4% | ≈ -4% | ≈ -5% |
Margins | n/d (likely loss-making) | Positive operating EBITDA | Positive (segment EBITDA before special items) | Positive |
R&D intensity | n/d (likely >100% of revenue) | ≈ 8% | ≈ 10% | ≈ 6% |
Commercial RNAi product | None (pre-commercial) | No sprayable RNAi product | Trait-based RNAi | — |
Recent Developments
Trillium Ag issues very few press releases. Only the following developments in the 18-month window could be verified or reasonably dated. Earlier 2023 items are listed separately for context and are not counted as part of the window.
*Context: pre-window developments
Items with no reported events: * guidance revisions, litigation, regulatory actions, restructurings, layoffs and hiring announcements.



